Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

by Riad Salem, Daneng Li, Nicolas Sommer, Sairy Hernandez, Wendy Verret, Beiying Ding, Riccardo Lencioni
Published 2021-08-01

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

by Stephen P. Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry, Andrew X. Zhu
Published 2021-07-01